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Umbilical cord blood (UCB) may be collected and cryopreserved for years before use. In vitro and murine
models suggest that the duration of storage does not affect UCB progenitor cell performance; however, the
impact of UCB age on clinical outcomes has not been deﬁnitely deﬁned. This study sought to determine the
effect of UCB unit cryopreservation time on hematopoietic potency. We analyzed 288 single UCB units used
for transplantation from 1992 to 2013, with unit cryopreservation time ranging from .08 to 11.07 years. UCB
unit post-thaw characteristics were examined, including percent recovery of total nucleated cells (TNC). The
number of years the UCB unit spent in cryopreservation had no impact on TNC recovery nor UCB unit post-
thaw viability. Duration of cryopreservation also had no impact on neutrophil or platelet engraftment in
single UCB transplantations. These results show that UCB units can undergo cryopreservation for at least 10
years with no impact on clinical outcomes.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION clinical outcomes for cryopreserved units, but they only
The ﬁrst successful umbilical cord blood (UCB) trans-
plantation was performed in 1988 [1], and since that time,
the ability to cryopreserve and bank UCB units has remained
an essential component of their use in hematopoietic stem
cell transplantation. The use of UCB as a donor source has
continued to grow, and there are currently over one half a
million UCB units cryopreserved in the worldwide cord
blood inventory [2].
Although cryopreservation is universally practiced in cord
blood banking, the impact on progenitor cell function has
been only partially addressed. Broxmeyer et al. demon-
strated that UCB units stored for up to 20 years do not lose
function when used in vitro and in murine assays of pro-
genitor cell function [3,4], and the St. Louis group reported no
signiﬁcant inﬂuence on clinical outcome after short-term
cryopreservation [5]. Parmar et al. recently reported onedgments on page 53.
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ty for Blood and Marrow Transplantation.documented 15 UCB units older than 5 years [6]. Hence, there
is still no conclusive answer to the question of whether long-
term cryopreservation affects UCB transplantation outcomes.
Storage of UCB units comes at a ﬁnancial cost to cord blood
banks [7,8], which is ultimately passed on to the patient,
transplantation institution, and the health care system as a
whole [9-11]. If long-term cryopreservation is detrimental to
UCB transplantation outcomes, the current model of cord
blood banking must be called into question. Alternatively, if
the duration of cryopreservation has no impact on clinical
outcomes, this provides evidence for cord blood banks to
continue the current model of cryopreservation, long-term
storage, and distribution of UCB units, to provide a rapidly
accessible donor source for transplant recipients worldwide.
In this study, we set out to determinewhether duration of
cryopreservation inﬂuenced single UCB transplantation
outcomes. We also examined the effect of cryopreservation
on post-thaw UCB unit characteristics.METHODS
Study Design
This was a retrospective review of 416 patients who underwent single
UCB transplantation at the University of Minnesota between 1992 and 2013.
Reasons for exclusion from the analysis included no available date of
Figure 1. Umbilical cord blood units by duration of cryopreservation. A total of
62 umbilical cord blood units were cryopreserved for more than 5 years.
R. Mitchell et al. / Biol Blood Marrow Transplant 21 (2015) 50e54 51collection for the UCB unit (n ¼ 125) and patients who did not receive
conditioning before receiving the UCB unit (n ¼ 3). Patients were treated on
protocols approved by the University of Minnesota institutional review
board, and written consent was obtained from all patients, their parents, or
guardians in accordance with the Declaration of Helsinki.
UCB Unit Processing
On delivery of UCB units to the University of Minnesota Molecular and
Cellular Therapeutics facility, units were inspected and then transferred and
maintained in vapor phase of liquid nitrogen storage until the day of infusion.
All UCB units were thawed and washed per the method of Rubinstein et al.
[12]. Before the wash, ABO/Rh typing of the unit was performed. After theV
ia
bi
lit
y 
(%
) 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
UCB duration of cryopreservation (years)
0.1-1.0 1.1-2.0 2.1-3.0 3.1-4.0 4.1-5.0 5.1-6.0 6.1-7.0 7.1-8.0 8.1-9.0 9.1-10.0 >10 
P = .58 
T
N
C
 r
ec
ov
er
y 
(%
)
0 
20 
40 
60 
80 
100 
120 
UCB duration of cryopreservation (years) 
0.1-1.0 1.1-2.0 2.1-3.0 3.1-4.0 4.1-5.0 5.1-6.0 6.1-7.0 7.1-8.0 8.1-9.0 9.1-10.0 >10 
P = .98 
Figure 2. Post-thaw nucleated cell viability (A) and total nucleated cell re-
covery (B) based on umbilical cord blood unit duration of cryopreservation.
There was no statistically signiﬁcant difference in post-thaw nucleated cell
viability (P ¼ .58) or total nucleated cell recovery (P ¼ .98) based on duration of
cryopreservation.wash and before release for infusion, samples were taken for assessment of
viability, total nucleated cell dose (TNC), CD34þ dose, and colony-forming
units-granulocyte macrophage (CFU-GM). Viability was assessed using the
acridine orange and propidium iodide method [13] and 7-aminoactinomycin
D (by ﬂow cytometry). Flow cytometry was performed as per the Interna-
tional Society of Hematotherapy and Graft Engineering speciﬁcations using a
dual platform, with ammonium chloride lysis for red cells followed by
washing and staining.
Deﬁnitions and Outcome Analysis
UCB units were analyzed based on the duration of cryopreservation of
the UCB unit. The TNC recovery was deﬁned as the total TNC recovered at
thaw, expressed as a percentage of the total TNC count reported before
freezing.
Neutrophil and platelet engraftment were deﬁned as previously
described [14-16]. Cox regression analysis was used to perform univariate
and multivariate analysis of patient and UCB unit factors and their inﬂuence
on outcomes. The following variables were assessed for their association
with neutrophil and platelet engraftment: duration of cryopreservation,
post-thaw TNC/kg, post-thaw CD34þ/kg, viability post-thaw, post-thaw
CFU/kg, UCB unit-recipient ABO match, UCB unit-recipient HLA match, year
of transplantation, type of conditioning regimen used, recipient gender,
recipient age, and recipient cytomegalovirus status. After 2005, patients
undergoing UCB transplantation at the University of Minnesota have not
routinely received antithymocyte globulin as part of their myeloablative
conditioning regimen. As such, year of transplantation was examined as
patients who underwent hematopoietic stem cell transplantation before
2006 compared with the more recent era.
RESULTS
Cell Recovery
There were 288 single UCB transplantations eligible for
analysis, with the duration of cryopreservation of the UCB
units ranging from .08 to 11.07 years (Figure 1). The median
post-thaw values for TNC were 11.3  108 cells (range, .97 to
38.41) and 12.9  106 cells (range, .18 to 131.5) for CD34þ
cells. The median post-thaw nucleated cell viability for the
cohort was 72% (range, 30% to 94%) and median post-thaw
total CFU-GM was 1.1  106 (range, 0 to 58.81). The median
TNC recovery was 76% (range, 30% to 108%). Duration of
cryopreservation of the UCB unit had no signiﬁcant impact
on the median post-thaw TNC (P ¼ .22), CD34þ (P ¼ .28), or
CFU-GM (P ¼ .68). Duration of cryopreservation of the UCB
unit also had no impact on post-thaw nucleated cell viability
and TNC recovery (Figure 2A,B).
Neutrophil Engraftment
Neutrophil engraftment for the cohort was 94% (95%
conﬁdence interval, 91% to 96%), with a median time to
neutrophil recovery of 20 days (range, 0 to 41). When
duration of cryopreservation of the UCB unit was analyzed as
a continuous variable in multivariate analysis, there was no
impact on neutrophil engraftment (P ¼ .15, data not shown).
UCB units were also analyzed in tertiles based on time spent
in cryopreservation (0 to 2 years, 2.1 to 4 years,>4 years) and
tested in univariate (Table 1) and multivariate analysis
(Table 2). There was no association of duration of cryopres-
ervation on the probability of neutrophil engraftment. Other
covariates, including CD34þ dose, CFU-GM, and year of
transplantation were independently signiﬁcant factors
identiﬁed in multivariate analysis (Table 2). Duration of
cryopreservation of the UCB unit also had no signiﬁcant
impact on time to neutrophil engraftment (Figure 3A).
Platelet Engraftment
Platelet engraftment at 1 year was 74% for the cohort (95%
conﬁdence interval, 67% to 81%), with a median time to
platelet recovery of 48 days (range, 10 to 224). When
analyzed as a continuous variable in multivariate analysis,
Table 1
Univariate Analysis for Neutrophil Engraftment
Parameter Engraftment
Rate (95% CI)
P Value
UCB unit cryopreservation, yr
0-2 94% (89-98) .21
2.1-4 96% (90-99)
>4 92% (85-97)
TNC (107/kg)
<2.5 90% (78-97) .02
2.5 95% (92-97)
CD34þ (105/kg)
<2.5 89% (79-96) <.01
2.5 96% (93-98)
Post-thaw viability
<75% 92% (88-96) .86
75% 96% (91-99)
CFU-GM (106/kg)
<5.0 92% (87-96) <.01
5.0 97% (93-99)
HLA matching
6/6 match 93% (86-97) .15
5/6 or less 95% (91-97)
ABO match
Match 92% (86-96) .03
Minor mismatch 96% (91-99)
Major mismatch 94% (88-98)
Conditioning regimen
Myeloablative 95% (66-82) .30
Reduced intensity 92% (58-93)
Year of transplantation
Before 2006 95% (90-98) .08
2006-2013 94% (89-97)
Recipient CMV
Positive 92% (87-96) .52
Negative 95% (91-98)
Recipient gender
Male 95% (91-98) .71
Female 93% (88-97)
Recipient age, yr
<18 94% (91-97) .14
18 93% (83-98)
CI indicates conﬁdence interval; CMV, cytomegalovirus.
A
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on platelet engraftment at 1 year (P ¼ .94, data not shown).
Duration of cryopreservation of the UCB unit also had noTable 2
Multivariate Analysis for Neutrophil Engraftment
Parameter Hazard Ratio
(95% CI)
P Value
UCB unit cryopreservation, yr
0-2 1.00 .33
2.1-4 .90 (.65-1.24)
>4 .79 (.58-1.08)
TNC (107/kg)
<2.5 1.00 .36
2.5 1.25 (.78-1.99)
CD34þ (105/kg)
<2.5 1.00 .04
2.5 1.55 (1.02-2.35)
CFU-GM (106/kg)
<5.0 1.00 <.01
5.0 1.58 (1.19-2.11)
HLA matching
6/6 match 1.00 .36
5/6 or less 1.15 (.85-1.55)
Year of transplantation
Before 2006 1.00 <.01
2006-2013 .66 (.50-.87)
ABO match
Match 1.00 .51
Minor mismatch 1.16 (.85-1.58)
Major mismatch 1.18 (.85-1.64)signiﬁcance when analyzed in tertiles in univariate and
multivariate analysis (Tables 3 and 4). The only covariate that
was signiﬁcantly associated with platelet engraftment in the
multivariate analysis was CFU-GM (Table 2B). Although the
time to platelet engraftment was signiﬁcantly different based
on duration of cryopreservation of the UCB unit (P¼ .03), this
was driven by delayed recovery in the UCB units cry-
opreserved for 4.1 to 5 years compared with units cry-
opreserved for shorter or longer time periods. Thus, there
was no prolongation of time to platelet engraftment based
on the duration of cryopreservation (Figure 3B).DISCUSSION
In this study, we examined the engraftment capacity and
kinetics of UCB units that were collected and stored for up to
12 years before use. We found that duration of storage,
however, had no obvious impact on cellular recovery or
engraftment after UCB transplantation. These results are in
line with preclinical studies published by Broxmeyer et al.
[3,4], as well a recent small clinical study [6], and support the
use of cryopreserved UCB as a reliable, rapidly accessible
donor source. Each UCB unit collected by cord blood banks
increases the available donor pool, in contrast to the pool of
unrelated donors, which is subject to ongoing donor attrition0.1-1.0 1.1-2.0 2.1-3.0 3.1-4.0 4.1-5.0 5.1-6.0 6.1-7.0 7.1-8.0 8.1-9.0 9.1-10.0 >10 
P =.03
B
Figure 3. Time to neutrophil (A) and platelet (B) engraftment based on um-
bilical cord blood unit duration of cryopreservation. (A) There was no statis-
tically signiﬁcant difference in time to neutrophil engraftment based on
duration of cryopreservation (P ¼ .38). (B) Umbilical cord blood units that were
cryopreserved for 4.1 to 5 years had a longer time to platelet engraftment than
units that were cryopreserved for shorter or longer time periods (P ¼ .03).
Table 3
Univariate Analysis for Platelet Engraftment at One Year
Parameter Engraftment
Rate (95% CI)
P Value
UCB unit cryopreservation, yr
0-2 75% (64-87) .89
2.1-4 72% (59-84)
>4 76% (63-89)
TNC (107/kg)
<2.5 62% (43-80) .10
2.5 76% (69-84)
CD34þ (105/kg)
<2.5 74% (57-92) .77
2.5 75% (67-83)
Post-thaw viability
<75% 75% (66-85) .67
75% 73% (62-85)
CFU-GM (106/kg)
<5.0 72% (61-82) <.01
5.0 82% (71-92)
HLA matching
6/6 match 81% (68-95) .05
5/6 or less 72% (63-80)
ABO match
Match 69% (57-81) .63
Minor mismatch 74% (62-86)
Major mismatch 80% (67-93)
Conditioning regimen
Myeloablative 74% (66-82) .02
Reduced intensity 76% (58-93)
Year of transplantation
Before 2006 71% (60-81) .04
2006-2013 77% (67-87)
Recipient CMV
Positive 70% (60-80) .14
Negative 78% (68-88)
Recipient gender
Male 74% (65-84) .38
Female 74% (64-85)
Recipient age, yr
<18 76% (68-84) .76
18 64% (46-81)
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continue to make UCB transplantation more accessible,
particularly for minority groups [19].Table 4
Multivariate Analysis for Platelet Engraftment at One Year
Parameter Hazard Ratio
(95% CI)
P Value
UCB unit cryopreservation, yr
0-2 1.00
2.1-4 .96 (.66-1.39) .81
>4 .87 (.63-1.21) .42
TNC (107/kg)
<2.5 1.00 .10
2.5 1.53 (.92-2.53)
CD34þ (105/kg)
<2.5 1.00 .29
2.5 .80 (.52-1.21)
CFU-GM (106/kg)
<5.0 1.00 .01
5.0 1.54 (1.13-2.11)
HLA matching
6/6 match 1.00 .07
5/6 or less .74 (.54-1.02)
Year of transplantation
Before 2006 1.00 .61
2006-2013 .92 (.68-1.25)
ABO match
Match 1.00
Minor mismatch .97 (.67-1.41) .87
Major mismatch 1.19 (.84-1.67) .33The characteristics of the UCB unit are vital to successful
transplantation [20-25]. In this study, we also demonstrate
that the length of cryopreservation did not signiﬁcantly
affect viability, TNC recovery, or CFU-GM analysis in a clinical
laboratory, which is supported by previous studies per-
formed in research laboratories [3,4]. These results question
the cord bank practice of considering UCB units outdated
after 10 years [26] and the general practice of avoiding older
UCB units for fear of poor clinical results. Thus, our study
provides further evidence that long-term cryopreservation of
UCB units is not detrimental to outcomes and suggests that
each UCB unit should be assessed on its individual charac-
teristics (HLA match, TNC, CD34þ, etc.) but not on the dura-
tion of cryopreservation of the unit.
One of the limitations of this study is the heterogeneous
nature of the patient population, which did not allow us to
compare outcomes in relation to graft-versus-host disease,
transplantation-related mortality, relapse, or survival. Our
study also included relatively few UCB units that had been
cryopreserved for >10 years, which makes it is difﬁcult to
extrapolate the conclusions to UCB units that have been cry-
opreserved formore than a decade. Itmust be stated, however,
that there is no evidence to contradict the use of UCB units
older than 10 years, and preclinical data suggest that these
products remain viable and potent [4]. In reviewing UCB unit
characteristics, itwasnotpossible to analyze recoveryofCD34þ
or CFU after cryopreservation, as the heterogeneous nature of
measurement techniques used at different cord collection
centersmakes it impossible to accuratelycompare thedifferent
prefreeze values. There were also a signiﬁcant number of UCB
units that did not have a date of collection (n¼ 125) and so had
to be omitted from the analysis. However, almost all of these
units were collected and subsequently used in the earliest
years of UCB transplantation, without undergoing long-term
cryopreservation, and so they would not have contributed to
the data set in a meaningful way. Our study also excluded
units used in double UCB transplantations, as this removed
UCB unit interaction as a potential confounding factor in our
analysis. Hence, the impact of long-term cryopreservation of
the UCB unit in double UCB transplantation remains unclear.
Our study demonstrated that the amount of time a UCB
unit spends in cryopreservation, up to 10 years, has no sig-
niﬁcant impact on engraftment outcomes. These results
support the use of UCB units that have undergone long-term
cryopreservation and should provide reassurance to clini-
cians in the ﬁeld of UCB transplantation.
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